NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

iclight,

Convenient that you forget that enrollment was closed and that surgery was done quickly leaving few options. Her tumor was benign in 2015 meaning non qualifying for the L trial and upon recurrence became diagnosed as GBM after her 2018 surgery which was well after the close of enrollment. Duke’s trial failed and I know of someone else that was in it that did not survive beyond normal SOC for their situation. So keep phishing but for the sake of patients you might want to consider the fact that L actually creates a pathway to a cure for some and at least better prognosis for many others. This statement is based on the data which was peer reviewed by JAMA Oncology meaning that conclusions based the methods and measures used to make them were validated as legit; ). Best wishes.